Techniques have been developed to identify stem cells within tumors and primary prostate cancer cell lines by utilizing the over-expression of the integrin α2β1 and CD133 as markers.[85] However, the limited number of prostate cancer stem cells available (<0.1% of tumor bulk) has limited profiling studies to date. This evidence concerns the gene PROM1 and Familial prostate cancer.